会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明公开
    • 엘-아스코빌-2-인산에스테르마그네슘염의 제조방법
    • L-抗坏血酸-2-磷酸盐镁盐及其中间体的制备方法
    • KR1020040044592A
    • 2004-05-31
    • KR1020020072649
    • 2002-11-21
    • 주식회사 엔지켐생명과학
    • 이태석육진수이종수유창현이주철이철민이완희
    • C07D307/62
    • Y02P20/55
    • PURPOSE: Provided is a method for manufacturing L-ascorbyl-2-phosphoric ester magnesium salt which does not use ion exchange resin in desalting process, and simplifies processing steps and removes by-product easily while obtaining a high purity target compound. CONSTITUTION: A method for manufacturing L-ascorbyl-2-phosphoric ester magnesium salt comprises the steps of: reacting watersoluble 5,6-protective group-L-ascorbyl-2-phosphoric ester salt with calcium salt to thereby form 5,6 -protective group-L-ascorbyl-2-phosphoric ester calcium in a crystalline phase, and separate it from the reaction solution; dissolving the crystalline phase 5,6 -protective group-L-ascorbyl-2-phosphoric ester calcium in a solvent of phosphoric acid, and removing the protective group from the 5,6 -protective group-L-ascorbyl-2-phosphoric ester calcium; and adding magnesium salt to the reaction solution.
    • 目的:提供一种在脱盐工序中不使用离子交换树脂的L-抗坏血酸-2-磷酸酯镁盐的制造方法,简化加工工序,容易地除去副产物而获得高纯度目标化合物。 构成:L-抗坏血酸-2-磷酸镁盐的制造方法,其特征在于,将水溶性5,6-保护基-L-抗坏血酸-2-磷酸酯盐与钙盐反应,形成5,6-保护性 将L-抗坏血酸基-2-磷酸酯钙在结晶相中,并将其与反应溶液分离; 将结晶相5,6-保护基-L-抗坏血酸基-2-磷酸酯钙溶解在磷酸溶剂中,并从5,6-保护基-L-抗坏血酸-2-磷酸酯钙中除去保护基 ; 并向反应溶液中加入镁盐。
    • 19. 发明授权
    • 리세드론산 나트륨 헤미펜타하이드레이트의 제조방법
    • 制备磺酸钠盐酸盐的方法
    • KR100798855B1
    • 2008-01-28
    • KR1020070015327
    • 2007-02-14
    • 주식회사 엔지켐생명과학
    • 이태석육진수이종수유창현이주철이철민이완희
    • C07F9/576C07F1/04
    • C07F9/58
    • A method for preparing sodium risedronate hemipentahydrate is provided to simplify the preparation procedures, and improve reproducibility, production yield, purity and economical efficiency of preparation, so that the compound is useful for treating bone diseases and calcium metabolism disorders. A method for preparing sodium risedronate hemipentahydrate represented by the formula(1) comprises the steps of: suspending risedronic acid represented by the formula(2) in water, adding sodium base into the water, cooling the mixture to 0-10 deg.C, and stirring the mixture to prepare nucleated slurry of sodium risedronate hemipentahydrate; and adding a water mixable organic solvent to the slurry, wherein the sodium base is sodium hydroxide, sodium acetate or sodium 2-ethylhexanoic acid; and the water mixable organic solvent is methanol, ethanol, isopropanol, acetone, acetonitrile or tetrahydrofuran.
    • 提供了一种制备利塞膦酸钠半水合物的方法,以简化制备过程,提高制备的再现性,产率,纯度和经济效率,使化合物可用于治疗骨骼疾病和钙代谢紊乱。 由式(1)表示的利塞膦酸二水合二钠的方法包括以下步骤:将由式(2)表示的利塞膦酸悬浮于水中,将钠碱加入水中,将混合物冷却至0-10℃, 并搅拌该混合物以制备利塞膦酸钠半水合物的有核浆液; 并向该浆料中加入水可混合有机溶剂,其中钠碱为氢氧化钠,乙酸钠或2-乙基己酸钠; 水可混合有机溶剂为甲醇,乙醇,异丙醇,丙酮,乙腈或四氢呋喃。